Allergic March in Children: The Significance of Precision Allergy Molecular Diagnosis (PAMD@) in Predicting Atopy Development and Planning Allergen-Specific Immunotherapy DOI Open Access

Izabela Knyziak-Mędrzycka,

Emilia Majsiak, Božena Cukrowská

et al.

Nutrients, Journal Year: 2023, Volume and Issue: 15(4), P. 978 - 978

Published: Feb. 15, 2023

The allergic march is a progression of naturally occurring symptoms whose nature changes with age. classic typically begins in infancy and manifests the form atopic dermatitis food allergy. As immune tolerance develops over time, these conditions may resolve by age 3–5 years; however, they evolve into rhinitis bronchial asthma. Traditional diagnostic assessments, such as skin prick testing or serum allergen-specific immunoglobulin E (sIgE) level testing, are conducted to introduce effective treatment. Recent years saw emergence precision allergy molecular diagnosis (PAMD@), which assesses sIgE against allergenic molecules. This new technology helps more accurately evaluate patient’s profile, create precise dietary specifications personalize immunotherapy. review presents possible predictions regarding means controlling it based on PAMD@ results.

Language: Английский

Allergen Immunotherapy in Children User’s Guide DOI Creative Commons
Montserrat Álvaro‐Lozano, Cezmi A. Akdiş, Mübeccel Akdiş

et al.

Pediatric Allergy and Immunology, Journal Year: 2020, Volume and Issue: 31(S25), P. 1 - 101

Published: May 1, 2020

Abstract Allergen immunotherapy is a cornerstone in the treatment of allergic children. The clinical efficiency relies on well‐defined immunologic mechanism promoting regulatory T cells and downplaying immune response induced by allergens. Clinical indications have been well documented for respiratory allergy presence rhinitis and/or asthma, to pollens dust mites. Patients who had an anaphylactic reaction hymenoptera venom are also good candidates allergen immunotherapy. Administration currently mostly either subcutaneous injections or sublingual administration. Both methods extensively studied pros cons. Specifically children, choice method administration according patient's profile important. Although widely used, there need improvement. More particularly, biomarkers prediction success treatments needed. strength may be boosted use better adjuvants. Finally, novel formulations might more efficient improve adherence treatment. This user's guide reviews current knowledge aims provide guidance healthcare professionals taking care children undergoing

Language: Английский

Citations

269
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023 DOI Creative Commons

Sarah K. Wise,

Cecelia Damask,

Lauren T. Roland

et al.

International Forum of Allergy & Rhinology, Journal Year: 2023, Volume and Issue: 13(4), P. 293 - 859

Published: March 6, 2023

In the 5 years that have passed since publication of 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR-Allergic 2018), literature has expanded substantially. The ICAR-Allergic 2023 update presents 144 individual topics allergic rhinitis (AR), by over 40 from document. Originally presented also been reviewed updated. executive summary highlights key evidence-based findings recommendation full

Language: Английский

Citations

225
A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020 DOI Creative Commons
Ignacio J. Ansotegui,

Giovanni Melioli,

Giorgio Walter Canonica

et al.

World Allergy Organization Journal, Journal Year: 2020, Volume and Issue: 13(2), P. 100091 - 100091

Published: Feb. 1, 2020

Abstract

Precision allergy molecular diagnostic applications (PAMD@) is increasingly entering routine care. Currently, more than 130 allergenic molecules from 50 sources are commercially available for in vitro specific immunoglobulin E (sIgE) testing. Since the last publication of this consensus document, a great deal new information has become regarding topic, with over 100 publications in year alone. It thus seems quite reasonable to publish an update. imperative that clinicians and immunologists specifically trained allergology keep abreast rapidly evolving evidence PAMD@. PAMD@ may initially appear complex interpret; however, increasing experience, gained provides relevant allergist. This especially true food allergy, Hymenoptera selection allergen immunotherapy. Nevertheless, all sIgE tests, including PAMD@, should be evaluated within framework patient's clinical history, because sensitization does not necessarily imply allergies.

Language: Английский

Citations

118
Past, present, and future of allergen immunotherapy vaccines DOI Creative Commons
Yulia Dorofeeva, I.P. Shilovskiy, Inna Tulaeva

et al.

Allergy, Journal Year: 2020, Volume and Issue: 76(1), P. 131 - 149

Published: April 6, 2020

Allergen-specific immunotherapy (AIT) is an allergen-specific form of treatment for patients suffering from immunoglobulin E (IgE)-associated allergy; the most common and important immunologically mediated hypersensitivity disease. AIT based on administration disease-causing allergen with goal to induce a protective immunity consisting blocking IgG antibodies alterations cellular immune response so that patient can tolerate contact. Major advantages over all other existing treatments allergy are induces long-lasting protection prevents progression disease severe manifestations. cost effective because it uses patient´s own system potentially be used as preventive treatment. However, broad application limited by mainly technical issues such quality preparations risk inducing side effects which results in extremely cumbersome schedules reducing compliance. In this article we review progress made its beginning provide overview state art, needs further development, possible solutions available through molecular allergology. Finally, consider visions development towards prophylactic application.

Language: Английский

Citations

100
Molecular diagnosis for allergen immunotherapy DOI Open Access
Paolo Maria Matricardi, Stephanie Dramburg, Ekaterina Potapova

et al.

Journal of Allergy and Clinical Immunology, Journal Year: 2019, Volume and Issue: 143(3), P. 831 - 843

Published: March 1, 2019

Language: Английский

Citations

86
Molecular profiling of allergen-specific antibody responses may enhance success of specific immunotherapy DOI Creative Commons

Azahara Rodríguez-Domínguez,

Margot Berings, Alexander Rohrbach

et al.

Journal of Allergy and Clinical Immunology, Journal Year: 2020, Volume and Issue: 146(5), P. 1097 - 1108

Published: April 13, 2020

House dust mites (HDMs) are among the most important allergen sources containing many different allergenic molecules. Analysis of patients from a double-blind, placebo-controlled allergen-specific immunotherapy (AIT) study indicated that may benefit AIT to extents depending on their molecular sensitization profiles.Our aim was investigate in real-life setting whether stratification with HDM allergy according analysis enhance success.Serum and nasal secretion samples (n = 24) (at baseline, 7, 15, 33, 52 weeks) who had received 1 year treatment well-defined subcutaneous form (Alutard SQ 510) were tested for IgE IgG reactivity 15 microarrayed molecules ImmunoCAP Immuno-solid-phase Allergen Chip technology. subclass levels allergens peptides determined by ELISA, blocking assessed basophil activation. In vitro parameters related reduction symptoms combined symptom medication score visual analog scale score.Alutard 510 induced protective mainly against Dermatophagoides pteronyssinus (Der p) Der p 2 lesser extent 23, but not other such as 5, 21, showing better clinical efficacy sensitized only and/or compared having additional specificities.Stratification profiles monitoring AIT-induced responses success AIT.

Language: Английский

Citations

73
House dust mite allergy: The importance of house dust mite allergens for diagnosis and immunotherapy DOI Creative Commons
Huey‐Jy Huang, Eszter Sarzsinszky, Susanne Vrtala

et al.

Molecular Immunology, Journal Year: 2023, Volume and Issue: 158, P. 54 - 67

Published: April 27, 2023

House dust mite (HDM) allergy belongs to the most important allergies and affects approximately 65–130 million people worldwide. Additionally, untreated HDM may lead development of severe disease manifestations such as atopic dermatitis or asthma. Diagnosis immunotherapy allergic patients are well established but often hampered by use extracts that bad quality lack allergens. The individual allergens seems be a promising alternative natural allergen extracts, since they represent well-defined components can easily produced quantified. However, thorough characterization is required determine their clinical relevance identify those for correct diagnosis successful immunotherapy. This review gives an update on benefits patients.

Language: Английский

Citations

31
Recombinant allergens for immunotherapy: state of the art DOI Creative Commons
Yury V. Zhernov, Mirela Curin, Musa Khaitov

et al.

Current Opinion in Allergy and Clinical Immunology, Journal Year: 2019, Volume and Issue: 19(4), P. 402 - 414

Published: May 13, 2019

More than 30 years ago, the first molecular structures of allergens were elucidated and defined recombinant became available. We review state art regarding AIT with goal to understand why progress in this field has been slow, although there is huge potential for treatment allergen-specific prevention.On basis allergen structures, several strategies have developed advanced into clinical evaluation. In trials, promising results obtained synthetic derivatives inducing IgG antibodies, which interfered recognition by IgE whereas efficacy could not yet be demonstrated approaches targeting only T-cell responses. Available data suggest that many advantages over extract-based AIT.Clinical studies indicate allergen-based vaccines, are superior existing can respiratory, food venom allergy. Allergen-specific preventive based on vaccine induction tolerance horizon hold promise allergy prevented. However, limited lack resources needed studies, necessary development these innovative strategies.

Language: Английский

Citations

66
The allergenic activity and clinical impact of individual IgE-antibody binding molecules from indoor allergen sources DOI Creative Commons
Luis Caraballo, Rudolf Valenta, Leonardo Puerta

et al.

World Allergy Organization Journal, Journal Year: 2020, Volume and Issue: 13(5), P. 100118 - 100118

Published: April 29, 2020

A large number of allergens have been discovered but we know little about their potential to induce inflammation (allergenic activity) and symptoms. Nowadays, the clinical importance is determined by frequency intensity IgE antibody binding (allergenicity). This a rather limited parameter considering development experimental allergology in last 20 years criteria that support personalized medicine. Now it known some allergens, addition properties, can through non mediated pathways, which increase allergenic activity. There are several ways evaluate activity, among them provocation tests, demonstration non-IgE pathways inflammation, case control studies IgE-binding frequencies, animal models respiratory allergy. In this review explored current status basic research on activity indoor confirm that, for most them, important property has not investigated. However, during recent advances made field, conclude at least following, demonstrated: Der p 1, 2, 5 Blo t from HDMs; Per 10 P. americana; Asp f 3, 4 6 A. fumigatus; Mala s 8 13 M. sympodialis; Alt 1 alternata; Pen c chrysogenum; Fel d cats; Can dogs; Mus m mice Bos 2 cows. Defining other molecules necessary precision-medicine-oriented management allergic diseases.

Language: Английский

Citations

52
Comparison of house dust mite sensitization profiles in allergic adults from Canada, Europe, South Africa and USA DOI
Varun Muddaluru, Rudolf Valenta, Susanne Vrtala

et al.

Allergy, Journal Year: 2021, Volume and Issue: 76(7), P. 2177 - 2188

Published: Jan. 23, 2021

Sensitization to house dust mite (HDM) is a leading cause of allergic rhinitis and asthma. Despite more than 30 HDM-derived allergens having been identified date, specific therapeutic approaches do not yet take into account the local sensitization profiles patients. This study aimed identify patterns HDM in HDM-allergic adults living distinct geographic areas, inform development targeted diagnostic tools.Serum samples from 685 subjects Canada, Europe, South Africa, USA were tested for levels IgE 17 micro-arrayed by ImmunoCAP Immuno Solid-phase Allergen Chip (ISAC) technology.The results confirmed significant geographical variability IgE. In all major sensitizers group 1 2 Der p 23. 23 was frequent sensitizer: 64% had 23, 2.3% monosensitized it. dominant allergen (86% prevalence) 7 achieved status (56%). influenced asthmatic status, exposure, age, race-ethnicity smoking but BMI.Sensitization differ considerably among with being Africa. Such heterogeneity should be taken diagnosis treatment

Language: Английский

Citations

49